CANCER TREATMENT
IN INDIA

Over two decades, India has built a network of high-volume cancer centers with internationally trained specialists, modern technology, and costs far below Western markets, making it one of the most important destinations in the world for advanced cancer care.

“India offers a rare combination: advanced care, experienced doctors, and affordability that makes treatment realistically possible for families worldwide.”

• Access to Advanced Treatment

  Major centres offer modern radiation, robotic surgery, comprehensive molecular testing, immunotherapy, targeted drugs, transplant programmes, and increasingly cell therapies including CAR-T.

• Affordability

  The same or comparable treatment usually costs far less in India than in the US, UK, or most of Europe. For families paying out of pocket, this difference can be the deciding factor.

• Reduced Waiting Times

  In cancer, time matters. Indian centres can often begin diagnostic workup and treatment planning quickly, without the lengthy delays common in several countries.

• English-Speaking Clinical Environment

  English is the working language at most major private cancer centres, and established international patient departments handle visa letters, travel, billing, and follow-up support.

Modern cancer care in India covers all core treatment modalities, typically delivered through multidisciplinary teams of medical, surgical, and radiation oncologists working alongside pathologists and radiologists.

• Surgery and Surgical Oncology

  Strong depth across breast, head and neck, GI, gynaecological, urological, and thoracic cancers. Many centres perform complex high-risk procedures regularly — one of the strongest predictors of good surgical outcomes.

• Radiation Therapy

  Modern external beam techniques including IMRT, IGRT, VMAT, stereotactic radiosurgery, SBRT, and brachytherapy are widely available. The most advanced centres also offer proton therapy.

• Chemotherapy and Medical Oncology

  Full range of standard regimens. Most internationally used chemotherapy agents are available, frequently at significantly lower cost than in Western markets.

• Targeted Therapy and Immunotherapy

  Targeted drugs for EGFR, ALK, HER2, BRAF, and other alterations are available, contingent on proper molecular testing. Checkpoint inhibitors including PD-1/PD-L1 inhibitors are part of standard care across several cancers.

• Bone Marrow and Stem Cell Transplant

  India has well-established transplant programmes at multiple centres with significant experience in both adult and paediatric autologous and allogeneic BMT for leukaemias, lymphomas, and myeloma.

• Precision Oncology and Molecular Testing

  Comprehensive NGS-based molecular profiling — including TP53, MSI, PD-L1, HER2, EGFR, ALK, ROS1, BRAF, KRAS, NRAS, NTRK — is available at major centres and is increasingly essential before treatment decisions are finalised.

India is no longer only a destination for affordable standard care. It has moved decisively into advanced therapies, and in CAR-T cell therapy, it has become a global example.

“India now has its own approved CAR-T therapy, NexCAR19, one of the most affordable CAR-T treatments in the world.”

• CAR-T Cell Therapy — NexCAR19

  India approved NexCAR19 (actalycabtagene autoleucel) in October 2023 — its first indigenous CAR-T therapy, developed by ImmunoACT with IIT Bombay and Tata Memorial Hospital. It targets CD19 in relapsed/refractory B-cell lymphomas and leukaemias, with ~70% overall response rate and a favourable safety profile. Priced at ₹30–40 lakh (~$36,000–50,000) vs ~$400,000–500,000 in the US.

• Proton Therapy

  The Apollo Proton Cancer Centre in Chennai — first dedicated proton therapy facility in South Asia and the Middle East, opened 2019 — offers high-precision radiation with reduced dose to surrounding healthy tissue. Particularly valuable for tumours near critical structures, paediatric cancers, and some recurrent tumours.

• Robotic and Minimally Invasive Surgery

  Many leading centres offer robotic-assisted oncologic surgery — smaller incisions, less blood loss, shorter hospital stays, and faster recovery for suitable patients in prostate, colorectal, gynaecological, thoracic, and other cancers.

• Clinical Trials

  Leading Indian centres run active clinical trials across oncology, including immunotherapy combinations, novel targeted agents, and cell therapy protocols. Trial access can open options unavailable outside a research setting — and is worth checking at a specialist assessment.

Key figures that put India's cancer treatment landscape in context for international patients and families.

• ~$36K–50KNexCAR19 CAR-T Cost in IndiaCompared to $400,000–500,000 in the United States — making India one of the most affordable CAR-T destinations in the world.
• 70%NexCAR19 Overall Response RateObserved in the pivotal early-phase trial in relapsed/refractory B-cell lymphomas and leukaemias, with a notably favourable CRS and neurotoxicity profile.
• 2019Apollo Proton Centre OpenedThe Apollo Proton Cancer Centre in Chennai is the first dedicated proton therapy facility in South Asia and the Middle East.
• Oct 2023NexCAR19 CDSCO ApprovalIndia's drug regulator approved its first indigenous CAR-T therapy, developed at IIT Bombay in collaboration with Tata Memorial Hospital.

India has a number of well-regarded cancer hospitals across major cities. Rather than a single 'best' hospital, the right centre depends heavily on the specific cancer and treatment needed.

“A hospital that is excellent for one cancer may not be the best fit for another — matching the patient to the right centre is one of the most valuable parts of careful navigation.”

• High-Volume Experience in Your Specific Cancer

  Does the hospital have specific, high-volume experience with your exact cancer type and stage? Volume is one of the strongest predictors of good outcomes for complex procedures.

• Genuine Multidisciplinary Tumour Board

  Is care delivered through a real MDT review — not by a single specialist working alone? The best outcomes consistently come from coordinated oncology teams.

• Availability of the Specific Treatment Needed

  Are the specific treatments the patient may need — a particular surgery, radiation technique, transplant, cell therapy, or clinical trial — actually available there?

• Molecular Testing and Pathology Capability

  Does the centre have comprehensive NGS and molecular pathology, including the ability to run the relevant biomarker tests for the patient's cancer type?

• International Patient Infrastructure

  What is the centre's experience with international patients — including coordination, language support, visa letters, and follow-up planning after return home?

Indicative cost comparisons for key cancer treatments. Exact costs depend on cancer type, stage, treatment duration, and the centre. These figures are illustrative — a case-specific review gives a more accurate picture.

India is an excellent option for a very large share of cancer patients — but good navigation means being honest about both its strengths and where other options may be worth comparing.

For a patient travelling to India for cancer care, the journey follows a clear sequence. Understanding it in advance reduces stress and helps families plan confidently.

1. 1

   Medical Record Review

   Reports, scans, pathology, and treatment history are reviewed so the situation is understood and the right specialists can be identified. CancerFax does this at no cost.

2. 2

   Specialist Opinion and Treatment Planning

   Suitable centres and doctors review the case — often after a tumour board discussion — and propose a treatment direction with a clear rationale.

3. 3

   Identifying Testing Gaps

   Frequently, additional investigations are recommended before the plan is finalised — such as a current PET-CT, a fresh biopsy, or molecular testing that has not yet been done.

4. 4

   Logistics and Travel Preparation

   Medical visa support, travel, accommodation, scheduling, and hospital admission are arranged. CancerFax coordinates these alongside the hospital's international patient team.

5. 5

   Treatment Delivery

   The planned treatment is delivered with the length of stay depending on the therapy — from a short surgical admission to several weeks for a transplant or CAR-T programme.

6. 6

   Follow-Up and Monitoring Plan

   A follow-up plan is established — including what can be managed at home and what may require return visits — with clear communication between the Indian team and local doctors.

India is an excellent option for a very large share of patients. But for certain advanced, experimental, or treatment-refractory cases, comparing India with other international corridors — particularly China — can reveal meaningful additional options.

• China as a Complementary Corridor

  China has become a significant centre for a wide range of cell and gene therapies, cancer clinical trials, and approaches in earlier stages of availability elsewhere. For complex, relapsed, or hard-to-treat disease, comparing what is available in India with options in China before deciding is often worthwhile.

• CancerFax Covers Both Corridors

  CancerFax supports patients across the India and China corridors, as well as other international centres. This allows for an objective comparison of genuine options — so families can choose with clear information rather than guesswork.

Frequently Asked Questions

The most common questions from patients and families considering cancer treatment in India.

CancerFax supports patients and families navigating cancer treatment in India in their own language — from the first report review to post-treatment follow-up.

• 🇬🇧English
• 🇮🇳Hindi
• 🇸🇦Arabic
• 🇧🇩Bengali
• 🇷🇺Russian
• 🇨🇳Chinese (Mandarin)
• 🇳🇬Swahili / East Africa
• 🇮🇷Farsi / Persian

In-depth guides covering every aspect of cancer care in India — from specific therapies and hospital choices to costs, clinical trials, and international access.